Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Pres, Prod Dev & Med Aff & CMO | July 26, 2021 | July 29, 2021 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | July 01, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date July 26, 2021 · Filed July 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 689,078 |
Reported balance
After 2021-07-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-26 · Exercise / conversion · Acquired 40,000 · Balance 689,078 F1: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2023-02-10 | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-26 · Exercise / conversion · Disposed 40,000 · Balance 0 F3: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 14,880 |
Reported balance
Holding disclosure · report date 2021-07-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,880 F2: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 23, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of July 23, 2021.
F3: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.
GENOCEA BIOSCIENCES, INC.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01 | Direct | 15,000 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2020 Filed Jan 10, 2020 01:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $17.96 | $898,000.00 |
DisclosureSEC source: 0000939767-20-000002 · wf-form4_157861964149710.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,122 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.62 to $18.25. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 01:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $5.51 | $275,500.00 |
DisclosureSEC source: 0000939767-20-000002 · wf-form4_157861964149710.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 4,027 | $17.67 | $71,157.09 |
DisclosureSEC source: 0000939767-19-000204 · wf-form4_157567819018369.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,122 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 4, 2019. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 15,592 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000204 · wf-form4_157567819018369.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,149 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 15,592 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that Exelixis, Inc. has achieved a net product revenue target over four consecutive fiscal quarters; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 4, 2019, the Committee convened to determine that the net product revenue target over four consecutive fiscal quarters had been achieved during the three months ended September 27, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2021, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-19-000198 · wf-form4_157559469250020.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 50,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 240,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $16.22 | $811,000.00 |
DisclosureSEC source: 0000939767-19-000198 · wf-form4_157559469250020.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,557 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.06 to $16.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $5.51 | $275,500.00 |
DisclosureSEC source: 0000939767-19-000198 · wf-form4_157559469250020.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 47,698 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 02:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,583 | $16.51 | $42,645.33 |
DisclosureSEC source: 0000939767-19-000196 · wf-form4_157387197627466.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,557 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 02:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 9,685 | $16.51 | $159,899.35 |
DisclosureSEC source: 0000939767-19-000196 · wf-form4_157387197627466.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,140 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 47,698 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 888 and 606 shares of common stock acquired on April 30, 2019 and October 31, 2019, respectively, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| November 04, 2019 Filed Nov 7, 2019 00:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $5.51 Strike: $5.51 | $275,500.00 |
DisclosureSEC source: 0000939767-19-000191 · wf-form4_157308810085909.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 50,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 240,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| November 04, 2019 Filed Nov 7, 2019 00:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $15.99 | $799,500.00 |
DisclosureSEC source: 0000939767-19-000191 · wf-form4_157308810085909.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,331 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.81 to $16.16. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 04, 2019 Filed Nov 7, 2019 00:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $5.51 | $275,500.00 |
DisclosureSEC source: 0000939767-19-000191 · wf-form4_157308810085909.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 71,448 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 01, 2019 Filed Oct 4, 2019 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $5.51 Strike: $5.51 | $165,300.00 |
DisclosureSEC source: 0000939767-19-000178 · wf-form4_157015097510585.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 160,000 shares of Exelixis, Inc. common stock, became exercisable as to 50% of such stock option on July 20, 2015 upon the satisfaction of one of the two performance goals set by the Compensation Committee. On December 10, 2014, the Compensation Committee determined that the second performance goal for the option had not, and would not, be achieved, resulting in the Reporting Person forfeiting the remaining 50% of such stock option. Read SEC document |
| October 01, 2019 Filed Oct 4, 2019 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 30,000 | $17.87 | $536,100.00 |
DisclosureSEC source: 0000939767-19-000178 · wf-form4_157015097510585.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,331 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| October 01, 2019 Filed Oct 4, 2019 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $5.51 | $165,300.00 |
DisclosureSEC source: 0000939767-19-000178 · wf-form4_157015097510585.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 71,448 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 12, 2019 Filed Sep 14, 2019 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,577 | $19.26 | $49,633.02 |
DisclosureSEC source: 0000939767-19-000168 · wf-form4_156842001268353.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,331 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 12, 2019. Read SEC document |
| September 12, 2019 Filed Sep 14, 2019 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 10,395 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000168 · wf-form4_156842001268353.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,908 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 10,395 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Compensation Committee's certification that Exelixis, Inc. has achieved a quarterly net product revenue target; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On September 12, 2019, the Committee convened to determine that the quarterly net product revenue target had been achieved during the three months ended June 28, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2020, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 71,448 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 63,109 | $7.18 Strike: $7.18 | $453,122.62 |
DisclosureSEC source: 0000939767-19-000086 · wf-form4_155433702016937.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,109 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 210,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 63,109 | $25.00 | $1,577,725.00 |
DisclosureSEC source: 0000939767-19-000086 · wf-form4_155433702016937.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 63,109 | $7.18 | $453,122.62 |
DisclosureSEC source: 0000939767-19-000086 · wf-form4_155433702016937.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:33 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000071 · wf-form4_155373321327183.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,109 Underlying: Common Stock · 100,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 195,409 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:33 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 100,000 | $23.14 | $2,314,000.00 |
DisclosureSEC source: 0000939767-19-000071 · wf-form4_155373321327183.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.31. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:33 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $7.18 | $718,000.00 |
DisclosureSEC source: 0000939767-19-000071 · wf-form4_155373321327183.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 23,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · derivative · entry 7 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 23,000 | $22.20 | $510,600.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 23,000 | $5.56 | $127,880.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · derivative · entry 6 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 100,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 100,000 | $21.66 | $2,166,000.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.39 to $22.02 Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 100,000 | $5.56 | $556,000.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 13,499 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000244 · wf-form4_154388521379385.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,499 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 13,499 | $21.02 | $283,748.98 |
DisclosureSEC source: 0000939767-18-000244 · wf-form4_154388521379385.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.82 to $21.27. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 13,499 | $5.04 | $68,034.96 |
DisclosureSEC source: 0000939767-18-000244 · wf-form4_154388521379385.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,479 | $17.45 | $43,258.55 |
DisclosureSEC source: 0000939767-18-000236 · wf-form4_154241785504509.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 22, 2016. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 01:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 9,296 | $17.45 | $162,215.20 |
DisclosureSEC source: 0000939767-18-000236 · wf-form4_154241785504509.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,992 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000224 · wf-form4_154120348927155.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,499 Underlying: Common Stock · 12,000 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 12,000 | $14.16 | $169,920.00 |
DisclosureSEC source: 0000939767-18-000224 · wf-form4_154120348927155.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.89 to $14.39. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 3, 2018 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 12,000 | $5.04 | $60,480.00 |
DisclosureSEC source: 0000939767-18-000224 · wf-form4_154120348927155.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000939767-18-000208 · wf-form4_153861170606263.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,499 Underlying: Common Stock · 12,000 shares Expires 2018-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 12,000 | $17.77 | $213,240.00 |
DisclosureSEC source: 0000939767-18-000208 · wf-form4_153861170606263.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.65 to $17.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 00:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 12,000 | $5.04 | $60,480.00 |
DisclosureSEC source: 0000939767-18-000208 · wf-form4_153861170606263.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 129,314 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-18-000201 · wf-form4_153679763393195.xml · derivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,314 Underlying: Common Stock · 129,314 shares Expires 2025-09-09 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| September 04, 2018 Filed Sep 7, 2018 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 22,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000190 · wf-form4_153627839293160.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2018-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. Read SEC document |
| September 04, 2018 Filed Sep 7, 2018 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 22,500 | $18.53 | $416,925.00 |
DisclosureSEC source: 0000939767-18-000190 · wf-form4_153627839293160.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.37 to $18.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 7, 2018 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 22,500 | $5.50 | $123,750.00 |
DisclosureSEC source: 0000939767-18-000190 · wf-form4_153627839293160.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-18-000186 · wf-form4_153481022676695.xml · derivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 50,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 160,000 shares of Exelixis, Inc. common stock, became exercisable as to 50% of such stock option on July 20, 2015 upon the satisfaction of one of the two performance goals set by the Compensation Committee. On December 10, 2014, the Compensation Committee determined that the second performance goal for the option had not, and would not, be achieved, resulting in the Reporting Person forfeiting the remaining 50% of such stock option. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $5.51 | $275,500.00 |
DisclosureSEC source: 0000939767-18-000186 · wf-form4_153481022676695.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 23:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 22,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000174 · wf-form4_153333799764968.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2018-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 23:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 22,500 | $20.56 | $462,600.00 |
DisclosureSEC source: 0000939767-18-000174 · wf-form4_153333799764968.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,288 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.42 to $20.78. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 23:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 22,500 | $5.50 | $123,750.00 |
DisclosureSEC source: 0000939767-18-000174 · wf-form4_153333799764968.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 22,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000123 · wf-form4_153066645574683.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 22,500 shares Expires 2018-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.